Kinnate Biopharma Inc. Stock Price, News & Analysis

Kinnate Biopharma Inc. (Nasdaq: KNTE) reported progress with its clinical programs and financial results for Q2 2022. The company initiated a Phase 1 trial for KIN-2787 in Taiwan and received Orphan Drug Designation from the U.S. FDA for this investigational therapy targeting stage IIb-IV melanoma. Kinnate had cash and equivalents of approximately $279.6 million as of June 30, 2022. Despite expanding its staff and clinical trials, the company reported a net loss of $27.1 million, up from $21.4 million in Q2 2021, along with increased R&D and administrative expenses.

Kinnate Biopharma Inc. (Nasdaq: KNTE) announced that CEO Nima Farzan will participate in the 'Bullseye - Targeted Oncology - Quanta of Targets' panel at the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022, at 10:20 a.m. ET. The Kinnate management team will also conduct investor meetings during the event. A live webcast will be available in the 'Investors and Media' section on the company's website, with a replay accessible for 30 days post-event. Kinnate focuses on developing targeted therapies for oncogenic drivers in cancer patients.

Kinnate Biopharma Inc (Nasdaq: KNTE) will participate in two investor conferences: the Jefferies Healthcare Conference on June 9, 2022, and the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022. Neha Krishnamohan, CFO, will represent the company at Jefferies, while CEO Nima Farzan will speak at Goldman Sachs. Investors can listen to live webcasts through the company's website, with replays available for 30 days. Kinnate focuses on developing small molecule kinase inhibitors for genomically defined cancers, leveraging its advanced research capabilities.

Kinnate Biopharma (Nasdaq: KNTE) announced key developments at the ASCO Annual Meeting, including the ongoing Phase 1 trial for its pan-FGFR inhibitor, KIN-3248, targeting cancers with FGFR2 and FGFR3 alterations. The trial aims to evaluate safety and efficacy in approximately 120 patients.

Additionally, the company presented preclinical results of KIN-2787 in combination with MEK inhibitors, demonstrating significant anti-tumor activity in NRAS-mutant melanoma models. This research underscores Kinnate's commitment to advancing targeted therapies for challenging cancers.

Kinnate Biopharma (KNTE) announced financial results for Q1 2022, reporting a net loss of $26.9 million, up from $17.5 million last year. As of March 31, 2022, cash, cash equivalents, and investments totaled approximately $302.4 million, projected to fund operations into early 2024. The company is focused on advancing its clinical pipeline, with initial data from the Phase 1 KN-8701 trial for KIN-2787 expected in Q4 2022, and the first patient dosed in the KN-4802 trial for KIN-3248. Kinnate aims to develop small molecule kinase inhibitors for genomically defined cancers.

Kinnate Biopharma Inc. (Nasdaq: KNTE) has initiated its Phase 1 clinical trial KN-4802, marking the first patient treatment of its lead FGFR product candidate, KIN-3248. This irreversible pan-FGFR inhibitor targets intrahepatic cholangiocarcinoma and urothelial carcinoma. The trial aims to evaluate safety, tolerability, and efficacy in patients with FGFR gene alterations. KIN-3248 is positioned to address unmet needs in cancer care by targeting specific FGFR mutations. The trial involves approximately 120 patients, and successful advancement could pave the way for new targeted therapies.

Kinnate Biopharma Inc. (Nasdaq: KNTE) presented three posters at the AACR Annual Meeting in New Orleans, showcasing the important role of their lead RAF kinase inhibitor, KIN-2787, in treating BRAF and/or NRAS-altered cancers like melanoma and non-small cell lung cancer. The data indicated that approximately 55% of BRAF alteration-positive patients have Class II and III alterations, which are linked to poorer outcomes. KIN-2787 aims to address the unmet needs in these patient populations and is currently involved in a clinical trial with a sample size of 155 patients.

Kinnate Biopharma (Nasdaq: KNTE) reported significant progress in its clinical trials and financials for 2021. The company initiated a Phase 1 trial for KIN-3248 and expects monotherapy data for KIN-2787 by Q3 2022. Full-year net loss was $89.8 million, an increase from $35.8 million in 2020, with R&D expenses at $67.2 million. Cash reserves stood at $324.9 million as of December 31, 2021. Key milestones for 2022 include combination studies and the initiation of trials in Greater China, reinforcing the company's commitment to advancing targeted oncology therapies.

Kinnate Biopharma (Nasdaq: KNTE) announced that abstracts related to its lead program, KIN-2787, a pan-RAF kinase inhibitor, have been accepted for presentation at the AACR Annual Meeting 2022 in New Orleans, scheduled for April 8-13. The presentations will cover important findings, including the prevalence of BRAF alterations in solid tumors and the design of KIN-2787's Phase 1/1b clinical study. KIN-2787 is aimed at treating patients with BRAF and NRAS mutations and has shown preclinical promise, targeting Class II and III alterations.